English

MOLECULIN BIOTECH, INC.

EDGAR

MBRX Current report (8-K) · filed 2026-10-30

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-6.66 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -12768000 USD Source
Operating Cash Flow: -6111000 USD Source

Cash and cash equivalents: 7.26 million USD 2026-06-30 Source
Exact value

7262000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 7.1 million shares 2026-06-30 Source
Exact value

7100000 shares

Reported share-count change

-76.50% · -23.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

30207494 shares · 2025-06-30· Source
7100000 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 0 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 0 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 0 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-30.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -25399000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -33560000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -49112000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -12845000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -7635000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-25.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -17369000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -10146000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -22735000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -17369000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -6111000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -12768000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -6111000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

0 USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Capital expenditure: -0 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: -0 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-30.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1327530 Filing: 000143774926008841 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1328200 Filing: 000143774926008841
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 7.51 million

Prior period

−USD 26.05 million

2024-01-01 – 2024-12-31
Current period

−USD 33.56 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-33560000 − -26048000 = -7512000 USD

-26048000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-33560000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Year-over-year change in Net income: -7512000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -33560000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1557381 Filing: 000143774926008841 Input fundies:NetIncome: -26048000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1637061 Filing: 000143774926008841
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.13 million

Prior period

−USD 23.86 million

2024-01-01 – 2024-12-31
Current period

−USD 22.74 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-22735000 − -23862000 = 1127000 USD

-23862000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-22735000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Year-over-year change in Operating cash flow: 1127000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -22735000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1397121 Filing: 000143774926008841 Input fundies:OperatingCashFlow: -23862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1648921 Filing: 000143774926008841
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 13,000

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

-0 − 13000 = -13000 USD

13000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Year-over-year change in Capital expenditure: -13000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: -0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400160 Filing: 000143774926008841 Input fundies:CapitalExpenditure: 13000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400939 Filing: 000143774926008841
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 25.1 million
Operating income −USD 25.1 million
Tax, interest and other Derived USD 8.46 million
Net income −USD 33.56 million

Cash

Operating cash flow −USD 22.74 million
Capital expenditure USD 0
Free cash flow Derived −USD 22.74 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	3883000 Derived	-3883000	43000 Derived	-3926000	-3786000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -3883000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -3926000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -3765000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 21000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	8653000 Derived	-8653000	1152000 Derived	-9805000	-7352000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -8653000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -9805000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -7324000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 28000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	15025000 Derived	-15025000	-3149000 Derived	-11876000	-12620000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -15025000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -11876000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -12203000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 417000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	17524000 Derived	-17524000	-4324000 Derived	-13200000	-17252000 Derived	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -17524000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -13200000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -17200000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 52000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	19742000 Derived	-19742000	-2342000 Derived	-17400000	-18176000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -19742000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -17400000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -17800000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 376000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	22968000 Derived	-22968000	-7068000 Derived	-15900000	-19019000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -22968000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -15900000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -19000000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 19000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	30640000 Derived	-30640000	-1615000 Derived	-29025000	-27706000 Derived	Source 2022-01-01 – 2022-12-31: 0 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -30640000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -29025000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -27639000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 67000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	29631000 Derived	-29631000	138000 Derived	-29769000	-23715000 Derived	Source 2023-01-01 – 2023-12-31: 0 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -29631000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -29769000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -23591000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 124000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	26641000 Derived	-26641000	-593000 Derived	-26048000	-23875000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -26641000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -26048000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -23862000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 13000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	25103000 Derived	-25103000	8457000 Derived	-33560000	-22735000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -25103000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -33560000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -22735000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: -0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20162016-12-31	Revenue	Revenue: 0 Open source
20172017-12-31	Revenue	Revenue: 0 Open source
20182018-12-31	Revenue	Revenue: 0 Open source
20192019-12-31	Revenue	Revenue: 0 Open source
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source
20222022-12-31	Revenue	Revenue: 0 Open source
20232023-12-31	Revenue	Revenue: 0 Open source
20242024-12-31	Revenue	Revenue: 0 Open source
20252025-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20232023-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20242024-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -3883000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -8653000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	Not reported	Operating Income: -15025000 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -17524000 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -19742000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -22968000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	Not reported	Operating Income: -30640000 Open source Revenue: 0 Open source
20232023-12-31	Operating margin	Not reported	Operating Income: -29631000 Open source Revenue: 0 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -26641000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -25103000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -3926000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -9805000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -11876000 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -13200000 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -17400000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -15900000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	Not reported	Net Income: -29025000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	Not reported	Net Income: -29769000 Open source Revenue: 0 Open source
20242024-12-31	Net margin	Not reported	Net Income: -26048000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -33560000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -3765000 Open source Capital Expenditure: 21000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -7324000 Open source Capital Expenditure: 28000 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -12203000 Open source Capital Expenditure: 417000 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -17200000 Open source Capital Expenditure: 52000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -17800000 Open source Capital Expenditure: 376000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -19000000 Open source Capital Expenditure: 19000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -27639000 Open source Capital Expenditure: 67000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -23591000 Open source Capital Expenditure: 124000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -23862000 Open source Capital Expenditure: 13000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -22735000 Open source Capital Expenditure: -0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -22.7M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-3765000	Operating Cash Flow: -3765000 Open source
20172017-12-31	Operating cash flow	-7324000	Operating Cash Flow: -7324000 Open source
20182018-12-31	Operating cash flow	-12203000	Operating Cash Flow: -12203000 Open source
20192019-12-31	Operating cash flow	-17200000	Operating Cash Flow: -17200000 Open source
20202020-12-31	Operating cash flow	-17800000	Operating Cash Flow: -17800000 Open source
20212021-12-31	Operating cash flow	-19000000	Operating Cash Flow: -19000000 Open source
20222022-12-31	Operating cash flow	-27639000	Operating Cash Flow: -27639000 Open source
20232023-12-31	Operating cash flow	-23591000	Operating Cash Flow: -23591000 Open source
20242024-12-31	Operating cash flow	-23862000	Operating Cash Flow: -23862000 Open source
20252025-12-31	Operating cash flow	-22735000	Operating Cash Flow: -22735000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -22.7M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-3786000	Operating Cash Flow: -3765000 Open source Capital Expenditure: 21000 Open source
20172017-12-31	Free cash flow	-7352000	Operating Cash Flow: -7324000 Open source Capital Expenditure: 28000 Open source
20182018-12-31	Free cash flow	-12620000	Operating Cash Flow: -12203000 Open source Capital Expenditure: 417000 Open source
20192019-12-31	Free cash flow	-17252000	Operating Cash Flow: -17200000 Open source Capital Expenditure: 52000 Open source
20202020-12-31	Free cash flow	-18176000	Operating Cash Flow: -17800000 Open source Capital Expenditure: 376000 Open source
20212021-12-31	Free cash flow	-19019000	Operating Cash Flow: -19000000 Open source Capital Expenditure: 19000 Open source
20222022-12-31	Free cash flow	-27706000	Operating Cash Flow: -27639000 Open source Capital Expenditure: 67000 Open source
20232023-12-31	Free cash flow	-23715000	Operating Cash Flow: -23591000 Open source Capital Expenditure: 124000 Open source
20242024-12-31	Free cash flow	-23875000	Operating Cash Flow: -23862000 Open source Capital Expenditure: 13000 Open source
20252025-12-31	Free cash flow	-22735000	Operating Cash Flow: -22735000 Open source Capital Expenditure: -0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

32.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	8.7%	Total Liabilities: 1433000 Open source Total Assets: 16393000 Open source
20172017-12-31	Liabilities / assets	12.1%	Total Liabilities: 2365000 Open source Total Assets: 19483000 Open source
20182018-12-31	Liabilities / assets	27.1%	Total Liabilities: 5313000 Open source Total Assets: 19585000 Open source
20192019-12-31	Liabilities / assets	38.3%	Total Liabilities: 9664000 Open source Total Assets: 25235000 Open source
20202020-12-31	Liabilities / assets	38.8%	Total Liabilities: 11271000 Open source Total Assets: 29031000 Open source
20212021-12-31	Liabilities / assets	6.1%	Total Liabilities: 5097000 Open source Total Assets: 84090000 Open source
20222022-12-31	Liabilities / assets	9.1%	Total Liabilities: 5231000 Open source Total Assets: 57422000 Open source
20232023-12-31	Liabilities / assets	31.8%	Total Liabilities: 12144000 Open source Total Assets: 38217000 Open source
20242024-12-31	Liabilities / assets	33.8%	Total Liabilities: 5717000 Open source Total Assets: 16925000 Open source
20252025-12-31	Liabilities / assets	32.2%	Total Liabilities: 7120000 Open source Total Assets: 22126000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.41× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	3.88×	Current Assets: 5222000 Open source Current Liabilities: 1345000 Open source
20172017-12-31	Current assets / current liabilities	3.75×	Current Assets: 8302000 Open source Current Liabilities: 2215000 Open source
20182018-12-31	Current assets / current liabilities	2.06×	Current Assets: 7974000 Open source Current Liabilities: 3878000 Open source
20192019-12-31	Current assets / current liabilities	3.78×	Current Assets: 13484000 Open source Current Liabilities: 3570000 Open source
20202020-12-31	Current assets / current liabilities	5.89×	Current Assets: 17198000 Open source Current Liabilities: 2920000 Open source
20212021-12-31	Current assets / current liabilities	20.02×	Current Assets: 72497000 Open source Current Liabilities: 3622000 Open source
20222022-12-31	Current assets / current liabilities	9.46×	Current Assets: 45596000 Open source Current Liabilities: 4819000 Open source
20232023-12-31	Current assets / current liabilities	3.86×	Current Assets: 26273000 Open source Current Liabilities: 6815000 Open source
20242024-12-31	Current assets / current liabilities	0.97×	Current Assets: 5194000 Open source Current Liabilities: 5359000 Open source
20252025-12-31	Current assets / current liabilities	1.41×	Current Assets: 9686000 Open source Current Liabilities: 6854000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 3.93 million Exact value Exact value: -3926000 USD 2016-01-01 – 2016-12-31: -3926000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2016-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -3926000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3926000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961718000027/mbrx-20171231.xml#250034 Filing: 000165961718000027 The citation records this snapshot. The page link may show a newer release later.	−USD 3.77 million Exact value Exact value: -3765000 USD 2016-01-01 – 2016-12-31: -3765000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2016-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -3765000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3765000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961718000027/mbrx-20171231.xml#249612 Filing: 000165961718000027 The citation records this snapshot. The page link may show a newer release later.	USD 21,000 Exact value Exact value: 21000 USD 2016-01-01 – 2016-12-31: 21000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2016-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 21000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961718000027/mbrx-20171231.xml#254544 Filing: 000165961718000027 The citation records this snapshot. The page link may show a newer release later.	−USD 3.79 million Calculation and evidence -3765000 − 21000 USD Exact free cash flow: -3786000 USD 2016-01-01 – 2016-12-31: -3765000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 21000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2016-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -3786000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -3765000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961718000027/mbrx-20171231.xml#249612 Filing: 000165961718000027 Input fundies:CapitalExpenditure: 21000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961718000027/mbrx-20171231.xml#254544 Filing: 000165961718000027 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 9.81 million Exact value Exact value: -9805000 USD 2017-01-01 – 2017-12-31: -9805000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2017-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -9805000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9805000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/mbx-20181231.htm#1391596 Filing: 000165961719000018 The citation records this snapshot. The page link may show a newer release later.	−USD 7.32 million Exact value Exact value: -7324000 USD 2017-01-01 – 2017-12-31: -7324000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2017-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -7324000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7324000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/mbx-20181231.htm#1282513 Filing: 000165961719000018 The citation records this snapshot. The page link may show a newer release later.	USD 28,000 Exact value Exact value: 28000 USD 2017-01-01 – 2017-12-31: 28000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2017-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 28000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 28000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/mbx-20181231.htm#1285886 Filing: 000165961719000018 The citation records this snapshot. The page link may show a newer release later.	−USD 7.35 million Calculation and evidence -7324000 − 28000 USD Exact free cash flow: -7352000 USD 2017-01-01 – 2017-12-31: -7324000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 28000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2017-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -7352000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7324000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/mbx-20181231.htm#1282513 Filing: 000165961719000018 Input fundies:CapitalExpenditure: 28000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/mbx-20181231.htm#1285886 Filing: 000165961719000018 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 11.88 million Exact value Exact value: -11876000 USD 2018-01-01 – 2018-12-31: -11876000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2018-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -11876000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11876000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/mbx-20191231.htm#1291215 Filing: 000165961720000066 The citation records this snapshot. The page link may show a newer release later.	−USD 12.2 million Exact value Exact value: -12203000 USD 2018-01-01 – 2018-12-31: -12203000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2018-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -12203000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12203000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/mbx-20191231.htm#1152323 Filing: 000165961720000066 The citation records this snapshot. The page link may show a newer release later.	USD 417,000 Exact value Exact value: 417000 USD 2018-01-01 – 2018-12-31: 417000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2018-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 417000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 417000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/mbx-20191231.htm#1156412 Filing: 000165961720000066 The citation records this snapshot. The page link may show a newer release later.	−USD 12.62 million Calculation and evidence -12203000 − 417000 USD Exact free cash flow: -12620000 USD 2018-01-01 – 2018-12-31: -12203000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 417000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2018-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -12620000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12203000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/mbx-20191231.htm#1152323 Filing: 000165961720000066 Input fundies:CapitalExpenditure: 417000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/mbx-20191231.htm#1156412 Filing: 000165961720000066 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 13.2 million Exact value Exact value: -13200000 USD 2019-01-01 – 2019-12-31: -13200000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2019-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -13200000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774921006940/mbrx20201231_10k.htm#1365732 Filing: 000143774921006940 The citation records this snapshot. The page link may show a newer release later.	−USD 17.2 million Exact value Exact value: -17200000 USD 2019-01-01 – 2019-12-31: -17200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2019-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -17200000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774921006940/mbrx20201231_10k.htm#1366249 Filing: 000143774921006940 The citation records this snapshot. The page link may show a newer release later.	USD 52,000 Exact value Exact value: 52000 USD 2019-01-01 – 2019-12-31: 52000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2019-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 52000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 52000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774921006940/mbrx20201231_10k.htm#1139579 Filing: 000143774921006940 The citation records this snapshot. The page link may show a newer release later.	−USD 17.25 million Calculation and evidence -17200000 − 52000 USD Exact free cash flow: -17252000 USD 2019-01-01 – 2019-12-31: -17200000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 52000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2019-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -17252000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17200000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774921006940/mbrx20201231_10k.htm#1366249 Filing: 000143774921006940 Input fundies:CapitalExpenditure: 52000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774921006940/mbrx20201231_10k.htm#1139579 Filing: 000143774921006940 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 17.4 million Exact value Exact value: -17400000 USD 2020-01-01 – 2020-12-31: -17400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2020-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -17400000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774922007103/mbrx20211231_10k.htm#1406491 Filing: 000143774922007103 The citation records this snapshot. The page link may show a newer release later.	−USD 17.8 million Exact value Exact value: -17800000 USD 2020-01-01 – 2020-12-31: -17800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2020-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -17800000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17800000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774922007103/mbrx20211231_10k.htm#1407102 Filing: 000143774922007103 The citation records this snapshot. The page link may show a newer release later.	USD 376,000 Exact value Exact value: 376000 USD 2020-01-01 – 2020-12-31: 376000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2020-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 376000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 376000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774922007103/mbrx20211231_10k.htm#1190676 Filing: 000143774922007103 The citation records this snapshot. The page link may show a newer release later.	−USD 18.18 million Calculation and evidence -17800000 − 376000 USD Exact free cash flow: -18176000 USD 2020-01-01 – 2020-12-31: -17800000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 376000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2020-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -18176000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17800000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774922007103/mbrx20211231_10k.htm#1407102 Filing: 000143774922007103 Input fundies:CapitalExpenditure: 376000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774922007103/mbrx20211231_10k.htm#1190676 Filing: 000143774922007103 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 15.9 million Exact value Exact value: -15900000 USD 2021-01-01 – 2021-12-31: -15900000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2021-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -15900000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -15900000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924002977/mbrx20240129_s1.htm#1591487 Filing: 000143774924002977 The citation records this snapshot. The page link may show a newer release later.	−USD 19 million Exact value Exact value: -19000000 USD 2021-01-01 – 2021-12-31: -19000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2021-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -19000000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924002977/mbrx20240129_s1.htm#1592104 Filing: 000143774924002977 The citation records this snapshot. The page link may show a newer release later.	USD 19,000 Exact value Exact value: 19000 USD 2021-01-01 – 2021-12-31: 19000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2021-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 19000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 19000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924002977/mbrx20240129_s1.htm#1429632 Filing: 000143774924002977 The citation records this snapshot. The page link may show a newer release later.	−USD 19.02 million Calculation and evidence -19000000 − 19000 USD Exact free cash flow: -19019000 USD 2021-01-01 – 2021-12-31: -19000000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 19000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2021-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -19019000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19000000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924002977/mbrx20240129_s1.htm#1592104 Filing: 000143774924002977 Input fundies:CapitalExpenditure: 19000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924002977/mbrx20240129_s1.htm#1429632 Filing: 000143774924002977 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 29.03 million Exact value Exact value: -29025000 USD 2022-01-01 – 2022-12-31: -29025000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2022-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -29025000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29025000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009044/mbrx20231231_10k.htm#1298467 Filing: 000143774924009044 The citation records this snapshot. The page link may show a newer release later.	−USD 27.64 million Exact value Exact value: -27639000 USD 2022-01-01 – 2022-12-31: -27639000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2022-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -27639000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27639000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009044/mbrx20231231_10k.htm#1244339 Filing: 000143774924009044 The citation records this snapshot. The page link may show a newer release later.	USD 67,000 Exact value Exact value: 67000 USD 2022-01-01 – 2022-12-31: 67000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2022-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 67000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 67000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009044/mbrx20231231_10k.htm#1247346 Filing: 000143774924009044 The citation records this snapshot. The page link may show a newer release later.	−USD 27.71 million Calculation and evidence -27639000 − 67000 USD Exact free cash flow: -27706000 USD 2022-01-01 – 2022-12-31: -27639000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 67000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2022-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -27706000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27639000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009044/mbrx20231231_10k.htm#1244339 Filing: 000143774924009044 Input fundies:CapitalExpenditure: 67000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774924009044/mbrx20231231_10k.htm#1247346 Filing: 000143774924009044 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 29.77 million Exact value Exact value: -29769000 USD 2023-01-01 – 2023-12-31: -29769000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2023-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -29769000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -29769000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774925008751/mbrx20241231_10k.htm#1333093 Filing: 000143774925008751 The citation records this snapshot. The page link may show a newer release later.	−USD 23.59 million Exact value Exact value: -23591000 USD 2023-01-01 – 2023-12-31: -23591000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2023-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -23591000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23591000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774925008751/mbrx20241231_10k.htm#1409688 Filing: 000143774925008751 The citation records this snapshot. The page link may show a newer release later.	USD 124,000 Exact value Exact value: 124000 USD 2023-01-01 – 2023-12-31: 124000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2023-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 124000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 124000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774925008751/mbrx20241231_10k.htm#1263699 Filing: 000143774925008751 The citation records this snapshot. The page link may show a newer release later.	−USD 23.72 million Calculation and evidence -23591000 − 124000 USD Exact free cash flow: -23715000 USD 2023-01-01 – 2023-12-31: -23591000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 124000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2023-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -23715000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23591000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774925008751/mbrx20241231_10k.htm#1409688 Filing: 000143774925008751 Input fundies:CapitalExpenditure: 124000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774925008751/mbrx20241231_10k.htm#1263699 Filing: 000143774925008751 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 26.05 million Exact value Exact value: -26048000 USD 2024-01-01 – 2024-12-31: -26048000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2024-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -26048000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -26048000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1637061 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	−USD 23.86 million Exact value Exact value: -23862000 USD 2024-01-01 – 2024-12-31: -23862000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2024-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -23862000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -23862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1648921 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	USD 13,000 Exact value Exact value: 13000 USD 2024-01-01 – 2024-12-31: 13000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2024-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: 13000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400939 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	−USD 23.88 million Calculation and evidence -23862000 − 13000 USD Exact free cash flow: -23875000 USD 2024-01-01 – 2024-12-31: -23862000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 13000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2024-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -23875000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -23862000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1648921 Filing: 000143774926008841 Input fundies:CapitalExpenditure: 13000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400939 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 33.56 million Exact value Exact value: -33560000 USD 2025-01-01 – 2025-12-31: -33560000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Net Income: -33560000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -33560000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1557381 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	−USD 22.74 million Exact value Exact value: -22735000 USD 2025-01-01 – 2025-12-31: -22735000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Operating Cash Flow: -22735000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22735000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1397121 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2025-01-01 – 2025-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400160 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.	−USD 22.74 million Calculation and evidence -22735000 − -0 USD Exact free cash flow: -22735000 USD 2025-01-01 – 2025-12-31: -22735000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MOLECULIN BIOTECH, INC. · 2025-12-31 MOLECULIN BIOTECH, INC. (edgar:1659617) Free cash flow: -22735000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:57:23Z Snapshot: 23b233584bdf7266605aece09ef823d654833a52c88703da93c6f8a3ae4bea96 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1659617?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22735000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1397121 Filing: 000143774926008841 Input fundies:CapitalExpenditure: -0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/mbrx20251231_10k.htm#1400160 Filing: 000143774926008841 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

94 filings · 2,220 latest values · 2,220 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001659617, 1659617, MBRX, edgar:1659617

Also known as MOLECULIN BIOTECH, INC., Moleculin Biotech, Inc.

MOLECULIN BIOTECH, INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation